Abstract: Left atrial thromboembolism seriously affects the quality of life of patients with atrial fibrillation, and even threatens their life safety. Recent studies have shown that biomarkers of left atrial thrombosis for atrial fibrillation can be used for early risk assessment in high-risk groups, and are important references for studying pathophysiological and mechanism of left atrial thrombosis in atrial fibrillation, as well as important indicators for measuring novel treatment methods. This article reviewed the application prospect of the biomarker system left atrial thrombosis for in atrial fibrillation in clinical practice and related clinical research progress.